Trial Profile

Children with HIV in Africa - Pharmacokinetics and Adherence of Simple Antiretroviral Regimens

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 26 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lopinavir/ritonavir (Primary)
Indications HIV infections
Focus Pharmacokinetics; Registrational
Acronyms CHAPAS2
Sponsors Cipla

Most Recent Events

03 Jun 2015 According to media release, lopinavir/ritonavir oral pellet formulation has received tentative approval from US FDA.
01 Jun 2014 Results published in the JAIDS.
06 Mar 2013 Results for the syrup versus sprinkle formulation analysis presented at the 20th Conference on Retroviruses and Opportunistic Infections.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com